Agios与Oscotec达成独家全球授权协议,共同开发并商业化新一代Syk抑制剂Cevidoplenib

美股速递
Jun 01

Agios Pharmaceuticals(简称Agios)已同Oscotec签署了一项独家全球授权协议,双方将携手推进新一代脾酪氨酸激酶抑制剂Cevidoplenib的开发与商业化进程。这一合作标志着两家公司在创新疗法领域迈出了重要一步,旨在加速该候选药物的全球研发与市场布局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10